Tedizolid: A new oxazolidinone antibiotic for skin and soft tissue infections

Consultant Pharmacist

Volumn 30, Issue 7, 2015, Pages 386-394

  Chahine, Elias B ^a   Sucher, Allana J ^b   Knutsen, Shannon D ^b  

^a PALM BEACH ATLANTIC UNIVERSITY   (United States)

^b REGIS UNIVERSITY   (United States)

Author keywords

Methicillin resistant Staphylococcus aureus; Oxazolidinone antibiotic; Skin and skin structure infections; Skin and soft tissue infections; Tedizolid

Indexed keywords

LINEZOLID; TEDIZOLID; ANTIINFECTIVE AGENT; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE;

ANEMIA; ANTIBACTERIAL ACTIVITY; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; CELLULITIS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG TOLERABILITY; FATIGUE; HUMAN; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; VOMITING; ADULT; DRUG EFFECTS; DRUG INTERACTION; GRAM POSITIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIOLOGY; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

ADULT; ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; ORGANOPHOSPHATES; OXAZOLES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84938914894     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2015.386     Document Type: Article

References (39)

1. Sievert DM, Ricks P, Edwards JR et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34:1-14.
2. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. Available at http://www.cdc.gov/drugresistance/threat-report-2013/index.html. Accessed November 7, 2014.
3. Dantes R, Mu Y, Belflower R et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013;173:1970-8.
4. Shales DM, Spellberg B. Overcoming the challenges to developing new antibiotics. Curr Opin Pharmacol 2012;12:522-6.
5. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 2011;1241:48-70.
6. Laube S, Farrell AM. Bacterial skin infections in the elderly: diagnosis and treatment. Drugs Aging 2002;19:331-42.
7. Rodriguez-Avial I, Culebras E, Betriu C et al. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012;67:167-9.
8. Kanafani ZA, Corey GR. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Exp Opin Invest Drugs 2012;21:515-22.
9. Schaadt R, Sweeney D, Shinabarger D et al. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009;53:3236-9.
10. SIVEXTROR (tedizolid phosphate) tablets and for injection [prescribing information]. Lexington, MA: Cubist Pharmaceuticals, Inc; June 2014.
11. Urbina O, Ferrandez O, Espona M et al. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. Drug Des Devel Ther 2013;7:243-65.
12. Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 2009;53:5265-74.
13. Shaw KJ, Poppe S, Schaadt R et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolidresistant strains. Antimicrob Agents Chemother 2008;52:4442-7.
14. Locke JB, Zurenko GE, Shaw KJ et al. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis 2014;58(S1):S35-42.
15. Locke JB, Finn J, Hilgers M et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother 2010;54:5337-43.
16. Cui L, Wang Y, Li Y et al. Cfr-mediated linezolid-resistance among methicillin-resistant coagulase-negative staphylococci from infections of humans. PLoS One 2013;8(2):e57096.
17. Smith LK, Mankin AS. Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. Antimicrob Agents Chemother 2008;52:1703-12.
18. Toh SM, Xiong L, Arias CA et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007;64:1506-14.
19. Morales G, Picazo JJ, Baos E et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010;50:821-5.
20. Long KS, Poehlsgaard J, Kehrenberg C et al. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006;50:2500-5.
21. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 2010;54:2063-9.
22. Livermore DM, Mushtaq S, Warner M et al. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 2009;63:713-5.
23. Thomson KS, Goering RV. Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins. Antimicrob Agents Chemother 2013;57:2892-5.
24. Jones RN, Moet GJ, Sader HS et al. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J Antimicrob Chemother 2009;63:716-20.
25. Prokocimer P, Bien P, DeAnda C et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR- 701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012;56:4608-13.
26. Flanagan S, Fang E, Munoz KA et al. Single- and multipledose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacother 2014;34:891-900.
27. Prokocimer P, Bien P, Surber J et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011;55:583-92.
28. Flanagan S, Bien PA, Munoz KA et al. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacother 2014;34:240-50.
29. Ong V, Flanagan S, Fang E et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos 2014;42:1275-84.
30. Flanagan S, Passarell J, Lu Q et al. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother 2014;58:6462-70.
31. Flanagan S, Minassian SL, Morris D et al. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother 2014;58:6471-6.
32. Prokocimer P, De Anda C, Fang E et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309:559-69.
33. Moran GJ, Fang E, Corey GR et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014;14:696-705.
34. Lodise TP, Fang E, Minassian SL et al. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother 2014;58:7198-204.
35. Flanagan S, McKee EE, Das D et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother 2015;59:178-85.
36. Flanagan S, Bartizal K, Minassian SL et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 2013;57:3060-6.
37. Two new drugs for skin and skin structure infections. Med Lett Drugs Ther 2014;56(1449):73-5.
38. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59:e10-52.
39. Liu C, Bayer A, Cosgrove SE et al; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55.